Financial Performance - The company's revenue increased approximately 48% from RMB 1,409 million for the year ended December 31, 2022, to RMB 2,080 million for the year ended December 31, 2023[21]. - The sales cost rose about 43% from RMB 814 million in 2022 to RMB 1,166 million in 2023, primarily due to the additional sales costs from the acquisition of Singapore BMX[22]. - Administrative expenses increased by 30% from RMB 814 million in 2022 to RMB 1,054 million in 2023, mainly due to professional service fees related to the acquisition of Singapore BMX[25]. - The company recorded an income tax credit of RMB 30 million for the year ended December 31, 2023, compared to an income tax expense of RMB 60 million for the year ended December 31, 2022[28]. - The company reported a net loss attributable to equity shareholders of RMB 191,685,000 for the year, compared to RMB 122,664,000 in 2022, highlighting increased financial challenges[55]. - The company reported a loss attributable to equity shareholders of RMB 191.685 million for the year, compared to a loss of RMB 122.664 million in the previous year[102]. - The company reported a net loss of RMB 193.349 million for the year, compared to a loss of RMB 123.163 million in the previous year, indicating a year-over-year increase in losses of approximately 56.8%[149]. - The company reported a net loss of RMB 193.35 million for the year ended December 31, 2023, compared to a loss of RMB 123.16 million in 2022[198]. Acquisition and Expansion - The acquisition of Singapore BMX was completed in June 2023 for a total consideration of USD 40 million, with potential adjustments based on cash changes, leading to a final price of USD 40,469,728[32]. - The company completed the acquisition of 100% equity in Singapore BMX, which is now a wholly-owned subsidiary[114]. - The company completed the acquisition of Singapore BMX and its seven subsidiaries on June 21, 2023, enhancing its product offerings and market reach[95]. Workforce and Employee Costs - Employee costs accounted for 28.3% of revenue in 2023, compared to 30.4% in 2022, with total employee costs of RMB 58,825 thousand[26]. - The company has 586 employees as of December 31, 2023, up from 479 employees in the previous year, indicating growth in workforce to meet business demands[35]. Research and Development - Research and development expenses rose to RMB 129,566,000 from RMB 119,773,000, reflecting a continued investment in innovation[53]. - The company plans to utilize RMB 284.8 million (15% of total proceeds) to enhance research and development capabilities and recruit talent in gene testing over the next one to three years[39]. - The company plans to enhance its research and development capabilities through mergers and acquisitions, aiming to build a leading global R&D system[146]. Product Development and Innovation - The DA500 high-throughput gene sequencer received approval from the National Medical Products Administration as a Class III medical device, capable of producing data throughput of 10Gb-150Gb[83]. - The company has developed the world's first smart liquid nitrogen tank, which has received medical device registration, addressing issues related to embryo management[107]. - The company has developed a new sperm quality testing method, enhancing the detection level of semen quality significantly[117]. - The Geri® incubator features six independent chambers, improving embryo development stability and increasing embryo utilization rates for patients[132]. - The company has developed a full-time differential incubator with 6 independent chambers, allowing for stable embryo cultivation and real-time monitoring without opening the incubator lid[166]. - The company has achieved significant technological advancements with its Live View system, allowing users to observe embryo growth in real-time[166]. - The new generation intelligent sperm analyzer has achieved precise detection of live sperm concentration, vitality, and morphology, addressing reliability issues in current testing methods[195]. Market Strategy and Sales - The company aims to enhance its international strategy by establishing a global sales network and promoting its products in overseas markets[48]. - The company plans to expand its sales network to cover 500 assisted reproductive centers in China, which is expected to significantly increase sales scale and market share[146]. - The company has established partnerships with over 40 distributors, covering more than 300 assisted reproductive institutions in China[85]. - The company has transitioned to a sales model through distributors, with 55 sales personnel in China as of December 31, 2023, down from 168 the previous year[85]. - The company plans to utilize 20% of the proceeds from the global offering for the continued sales and marketing of the PGT-A test kit in China, with an actual amount of HKD 156.3 million already used[67]. Financial Position and Liabilities - The company's total liabilities increased to RMB 179,727 thousand as of December 31, 2023, from RMB 106,291 thousand as of December 31, 2022[17]. - The company has no contingent liabilities as of December 31, 2023, indicating a stable financial position[33]. - The total non-current assets are reported at RMB 682.921 million, while current assets stand at RMB 252.262 million, indicating a solid asset base[151]. Regulatory Approvals and Certifications - The Geri® incubator has received registrations from the National Medical Products Administration, CE, FDA, and TGA[132]. - The company has obtained multiple product registrations in the fields of in vitro diagnostic reagents, active devices, and independent software[116]. - The company achieved a significant milestone by obtaining the first "National Innovative Medical Device Special Approval" for its PGT-A reagent kit, filling a clinical gap in China's third-generation IVF market[154]. Future Plans and Investments - The company plans to invest 10% of the proceeds for acquiring new technologies and experienced R&D personnel for production facilities[68]. - The company expects to fully utilize the unallocated proceeds within the next one to three years[67]. - The company aims to build a global production base covering the entire assisted reproduction industry chain, focusing on high-quality and scalable delivery capabilities[92]. - The company aims to expand its market presence in fertility preservation globally with automated ultra-low temperature embryo storage equipment capable of storing 30,000 to 50,000 gametes[167]. - The company plans to launch several new products, including PGT-A and PGT-M testing kits, with registrations expected in 2024 and 2025 respectively[185][187].
贝康医疗-B(02170) - 2023 - 年度业绩